2024-02-012025-01-312025-01-31false08375157ADVANCED HEALTHCARE PRODUCTS LTD2025-04-11falseiso4217:GBPxbrli:pure083751572024-02-01083751572025-01-31083751572024-02-012025-01-31083751572023-02-01083751572024-01-31083751572023-02-012024-01-3108375157bus:SmallEntities2024-02-012025-01-3108375157bus:AuditExempt-NoAccountantsReport2024-02-012025-01-3108375157bus:FullAccounts2024-02-012025-01-3108375157bus:PrivateLimitedCompanyLtd2024-02-012025-01-3108375157core:WithinOneYear2025-01-3108375157core:AfterOneYear2025-01-3108375157core:WithinOneYear2024-01-3108375157core:AfterOneYear2024-01-3108375157core:ShareCapital2025-01-3108375157core:SharePremium2025-01-3108375157core:RevaluationReserve2025-01-3108375157core:OtherReservesSubtotal2025-01-3108375157core:RetainedEarningsAccumulatedLosses2025-01-3108375157core:ShareCapital2024-01-3108375157core:SharePremium2024-01-3108375157core:RevaluationReserve2024-01-3108375157core:OtherReservesSubtotal2024-01-3108375157core:RetainedEarningsAccumulatedLosses2024-01-3108375157core:LandBuildings2025-01-3108375157core:PlantMachinery2025-01-3108375157core:Vehicles2025-01-3108375157core:FurnitureFittings2025-01-3108375157core:OfficeEquipment2025-01-3108375157core:NetGoodwill2025-01-3108375157core:IntangibleAssetsOtherThanGoodwill2025-01-3108375157core:ListedExchangeTraded2025-01-3108375157core:UnlistedNon-exchangeTraded2025-01-3108375157core:LandBuildings2024-01-3108375157core:PlantMachinery2024-01-3108375157core:Vehicles2024-01-3108375157core:FurnitureFittings2024-01-3108375157core:OfficeEquipment2024-01-3108375157core:NetGoodwill2024-01-3108375157core:IntangibleAssetsOtherThanGoodwill2024-01-3108375157core:ListedExchangeTraded2024-01-3108375157core:UnlistedNon-exchangeTraded2024-01-3108375157core:LandBuildings2024-02-012025-01-3108375157core:PlantMachinery2024-02-012025-01-3108375157core:Vehicles2024-02-012025-01-3108375157core:FurnitureFittings2024-02-012025-01-3108375157core:OfficeEquipment2024-02-012025-01-3108375157core:NetGoodwill2024-02-012025-01-3108375157core:IntangibleAssetsOtherThanGoodwill2024-02-012025-01-3108375157core:ListedExchangeTraded2024-02-012025-01-3108375157core:UnlistedNon-exchangeTraded2024-02-012025-01-3108375157core:MoreThanFiveYears2024-02-012025-01-3108375157core:Non-currentFinancialInstruments2025-01-3108375157core:Non-currentFinancialInstruments2024-01-3108375157dpl:CostSales2024-02-012025-01-3108375157dpl:DistributionCosts2024-02-012025-01-3108375157core:LandBuildings2024-02-012025-01-3108375157core:PlantMachinery2024-02-012025-01-3108375157core:Vehicles2024-02-012025-01-3108375157core:FurnitureFittings2024-02-012025-01-3108375157core:OfficeEquipment2024-02-012025-01-3108375157dpl:AdministrativeExpenses2024-02-012025-01-3108375157core:NetGoodwill2024-02-012025-01-3108375157core:IntangibleAssetsOtherThanGoodwill2024-02-012025-01-3108375157dpl:GroupUndertakings2024-02-012025-01-3108375157dpl:ParticipatingInterests2024-02-012025-01-3108375157dpl:GroupUndertakingscore:ListedExchangeTraded2024-02-012025-01-3108375157core:ListedExchangeTraded2024-02-012025-01-3108375157dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-02-012025-01-3108375157core:UnlistedNon-exchangeTraded2024-02-012025-01-3108375157dpl:CostSales2023-02-012024-01-3108375157dpl:DistributionCosts2023-02-012024-01-3108375157core:LandBuildings2023-02-012024-01-3108375157core:PlantMachinery2023-02-012024-01-3108375157core:Vehicles2023-02-012024-01-3108375157core:FurnitureFittings2023-02-012024-01-3108375157core:OfficeEquipment2023-02-012024-01-3108375157dpl:AdministrativeExpenses2023-02-012024-01-3108375157core:NetGoodwill2023-02-012024-01-3108375157core:IntangibleAssetsOtherThanGoodwill2023-02-012024-01-3108375157dpl:GroupUndertakings2023-02-012024-01-3108375157dpl:ParticipatingInterests2023-02-012024-01-3108375157dpl:GroupUndertakingscore:ListedExchangeTraded2023-02-012024-01-3108375157core:ListedExchangeTraded2023-02-012024-01-3108375157dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-02-012024-01-3108375157core:UnlistedNon-exchangeTraded2023-02-012024-01-3108375157core:NetGoodwill2025-01-3108375157core:IntangibleAssetsOtherThanGoodwill2025-01-3108375157core:LandBuildings2025-01-3108375157core:PlantMachinery2025-01-3108375157core:Vehicles2025-01-3108375157core:FurnitureFittings2025-01-3108375157core:OfficeEquipment2025-01-3108375157core:AfterOneYear2025-01-3108375157core:WithinOneYear2025-01-3108375157core:ListedExchangeTraded2025-01-3108375157core:UnlistedNon-exchangeTraded2025-01-3108375157core:ShareCapital2025-01-3108375157core:SharePremium2025-01-3108375157core:RevaluationReserve2025-01-3108375157core:OtherReservesSubtotal2025-01-3108375157core:RetainedEarningsAccumulatedLosses2025-01-3108375157core:NetGoodwill2024-01-3108375157core:IntangibleAssetsOtherThanGoodwill2024-01-3108375157core:LandBuildings2024-01-3108375157core:PlantMachinery2024-01-3108375157core:Vehicles2024-01-3108375157core:FurnitureFittings2024-01-3108375157core:OfficeEquipment2024-01-3108375157core:AfterOneYear2024-01-3108375157core:WithinOneYear2024-01-3108375157core:ListedExchangeTraded2024-01-3108375157core:UnlistedNon-exchangeTraded2024-01-3108375157core:ShareCapital2024-01-3108375157core:SharePremium2024-01-3108375157core:RevaluationReserve2024-01-3108375157core:OtherReservesSubtotal2024-01-3108375157core:RetainedEarningsAccumulatedLosses2024-01-3108375157core:NetGoodwill2023-02-0108375157core:IntangibleAssetsOtherThanGoodwill2023-02-0108375157core:LandBuildings2023-02-0108375157core:PlantMachinery2023-02-0108375157core:Vehicles2023-02-0108375157core:FurnitureFittings2023-02-0108375157core:OfficeEquipment2023-02-0108375157core:AfterOneYear2023-02-0108375157core:WithinOneYear2023-02-0108375157core:ListedExchangeTraded2023-02-0108375157core:UnlistedNon-exchangeTraded2023-02-0108375157core:ShareCapital2023-02-0108375157core:SharePremium2023-02-0108375157core:RevaluationReserve2023-02-0108375157core:OtherReservesSubtotal2023-02-0108375157core:RetainedEarningsAccumulatedLosses2023-02-0108375157core:AfterOneYear2024-02-012025-01-3108375157core:WithinOneYear2024-02-012025-01-3108375157core:Non-currentFinancialInstrumentscore:CostValuation2024-02-012025-01-3108375157core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-02-012025-01-3108375157core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-02-012025-01-3108375157core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-02-012025-01-3108375157core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-02-012025-01-3108375157core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-02-012025-01-3108375157core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-02-012025-01-3108375157core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-02-012025-01-3108375157core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-02-012025-01-3108375157core:Non-currentFinancialInstrumentscore:CostValuation2025-01-3108375157core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-01-3108375157core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-01-3108375157core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-01-3108375157core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-01-3108375157core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-01-3108375157core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-01-3108375157core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-01-3108375157core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-01-3108375157core:Non-currentFinancialInstrumentscore:CostValuation2024-01-3108375157core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-01-3108375157core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-01-3108375157core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-01-3108375157core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-01-3108375157core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-01-3108375157core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-01-3108375157core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-01-3108375157core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-01-3108375157bus:Director12024-02-012025-01-3108375157core:FurnitureFittingsToolsEquipment2024-01-3108375157core:FurnitureFittingsToolsEquipment2024-02-012025-01-3108375157core:FurnitureFittingsToolsEquipment2025-01-31

ADVANCED HEALTHCARE PRODUCTS LTD

Registered Number
08375157
(England and Wales)

Unaudited Financial Statements for the Year ended
31 January 2025

ADVANCED HEALTHCARE PRODUCTS LTD
Company Information
for the year from 1 February 2024 to 31 January 2025

Director

HASELDINE, Freya Leanne

Registered Address

6 Edison Village
Nottingham Science & Technology Park
Nottingham
NG7 2RF

Registered Number

08375157 (England and Wales)
ADVANCED HEALTHCARE PRODUCTS LTD
Balance Sheet as at
31 January 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Tangible assets349,22641,268
49,22641,268
Current assets
Stocks41,000867
Debtors542,85244,098
Cash at bank and on hand141,241181,269
185,093226,234
Creditors amounts falling due within one year6(157,139)(164,069)
Net current assets (liabilities)27,95462,165
Total assets less current liabilities77,180103,433
Creditors amounts falling due after one year7(32,929)(56,974)
Provisions for liabilities8(248)(305)
Net assets44,00346,154
Capital and reserves
Called up share capital22
Profit and loss account44,00146,152
Shareholders' funds44,00346,154
The financial statements were approved and authorised for issue by the Director on 11 April 2025, and are signed on its behalf by:
HASELDINE, Freya Leanne
Director
Registered Company No. 08375157
ADVANCED HEALTHCARE PRODUCTS LTD
Notes to the Financial Statements
for the year ended 31 January 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Interest income
Interest income is recognised using the effective interest rate method.
Operating leases
Where, substantially, all the risks and rewards of ownership of the asset do not transfer from the lessor to the company, the lease is treated as an operating lease. Rentals payable under operating leases are charged to the profit and loss account on a straight-line basis over the period of the lease.
Employee benefits
Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Current taxation
Current tax is recognised in profit or loss, except for taxes related to revaluations of land and buildings which are recognised in other comprehensive income. Current tax represents the amount of tax payable (receivable) in respect of taxable profit (loss) for the current, or past, reporting periods. Current tax is measured at the amount expected to be paid (recovered) using the tax rates and laws which have been enacted, or substantively enacted, by the balance sheet date. Where payments to HM Revenue and Customs exceed liabilities owed, an asset is recognised to the extent of the amount of tax recoverable.
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Reducing balance (%)Straight line (years)
Land and buildings-50
Fixtures and fittings25-
Office Equipment25-
Stocks and work in progress
Stock is valued at the lower of cost and estimated selling price less costs to complete and sell. The cost methodology employed by the entity is the first-in first-out method. Estimated selling price less costs to complete and sell are derived from the selling price which the goods would fetch in an open market transaction with established customers less the costs expected to be incurred to enable the sale to complete. Provision is made for slow-moving and obsolete items of stock. Such provisions are recognised in profit or loss. Work in progress is valued using the percentage of completion method and values are calculated using the lower of cost and estimated selling price less costs to complete and sell. When stocks are sold, the carrying amount of those stocks is recognised as an expense within cost of sales. This takes place in the same period that the associated revenue is recognised.
Trade and other debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Trade and other creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Share capital
Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.
Related parties
For the purposes of these financial statements, a related party could be a person or an entity. Careful consideration is given to the definition of a related party to ensure that all related party relationships, transactions and balances are identified.
2.Average number of employees

20252024
Average number of employees during the year35
3.Tangible fixed assets

Land & buildings

Fixtures & fittings

Office Equipment

Total

££££
Cost or valuation
At 01 February 2440,0001,5924,65446,246
Additions10,000--10,000
Disposals--(3,696)(3,696)
At 31 January 2550,0001,59295852,550
Depreciation and impairment
At 01 February 248009873,1914,978
Charge for year9671511801,298
On disposals--(2,952)(2,952)
At 31 January 251,7671,1384193,324
Net book value
At 31 January 2548,23345453949,226
At 31 January 2439,2006051,46341,268
4.Stocks

2025

2024

££
Finished goods1,000867
Total1,000867
5.Debtors: amounts due within one year

2025

2024

££
Trade debtors / trade receivables14,61414,666
Amounts owed by associates and joint ventures / participating interests9,789812
Other debtors18,44928,620
Total42,85244,098
6.Creditors: amounts due within one year

2025

2024

££
Trade creditors / trade payables37,85596,055
Bank borrowings and overdrafts38,7269,384
Amounts owed to related parties-434
Taxation and social security80,53457,296
Other creditors24-
Accrued liabilities and deferred income-900
Total157,139164,069
7.Creditors: amounts due after one year

2025

2024

££
Bank borrowings and overdrafts32,92956,974
Total32,92956,974
8.Provisions for liabilities

2025

2024

££
Net deferred tax liability (asset)248305
Total248305
9.Related party transactions
During the year interest free loans were made available to the business by directors of -£8,977 (2024 - £434) this amount was repaid by the director within 9 months of the year end date. There were also interest free loans to associated companies totalling £812 at the year end (2024 £812).